ARVO 2012 Abstract Search & Itinerary Builder
How to Create an Itinerary Account
(New Account must be created each year)
Prg Sch at a Glance
Initial Experience Using A Collagen Matrix Implant (Ologen
) As A Wound Modulator With Canaloplasty: 12 Month Results
Presentation Start/End Time:
Monday, May 07, 2012, 3:45 PM - 5:30 PM
Surgical Wound Healing
203 glaucoma: surgery or wound healing - GL
Matthew S. Johnson
, Steven Sarkisian
, Nathan Blessing
, James M. Rouse
Ophthalmology, Dean McGee Eye Institute, Oklahoma City, OK;
Ophthalmology, Oklahoma University Health Science Center, Oklahoma City, OK.
630 outflow: trabecular meshwork, 761 wound healing
To investigate the success rate of a collagen matrix implant as a wound modulator in canaloplasty.
A retrospective review was performed of 22 consecutive eyes with 12 months of follow up data after undergoing canaloplasty using collagen in the scleral lake. Main outcome measures included post-operative IOP, number of anti-glaucoma medications, and post-operative complications. Complete surgical success was defined as an IOP ≤ 21, 18, and 16 mm Hg without medications, and qualified success with or without medications.
The mean IOP dropped from 23.0 ± 7.0 mm Hg preoperatively to 13.4 ± 3.3 mm Hg at 12 months. Mean number of medications dropped from 1.8 ± 1.0 preoperatively to 0.59 ± 0.85 at 12 months. Complete surgical success was achieved in 54.5% of patients, all of whom had an IOP ≤ 16 mm Hg. The qualified success rate of an IOP ≤ 21, 18, and 16 mm Hg was 100%, 95.5%, and 72.7%, respectively. Post-operative complications included transient conjunctival leaks in 6 eyes, shallow anterior chamber in 1 eye, and bleb formation in 1 eye. Post-operative interventions included laser goniopuncture performed in 5 eyes, iridoplasty performed in 1 eye, and bleb revision performed in 1 eye. Mean IOP before goniopuncture was 32.4 ± 19.3 mmHg, and was 17.6 ± 7.9 mm Hg on the subsequent post-procedure visit.
Surgical success indicates a collagen matrix implant may be a useful adjunct in canaloplasty.
Matthew S. Johnson
, iScience (C), Optous (C);
James M. Rouse
This research was supported in part by Research to Prevent Blindness
Program Schedule at a Glance
When adding presentations to your Itinerary, please click "Add Checked Selections to My Itinerary" on
page of your search results.
= ePoster Presenter
e-Posters will be available at 6:00 PM ET on the day of the abstract’s scheduled poster presentation and will remain active through June 30, 2012.
© Association for Research in Vision and Ophthalmology, Inc., all rights reserved.
to access the version of record. For permission to reproduce any abstract, contact the ARVO Office at
The Online Abstract Submission and Invitation System
© 1996 - 2013 Coe-Truman Technologies, Inc. All rights reserved.